Advertisement
NUVL vs XBI
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NUVL is a Hold and XBI is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NUVL’s FA Score shows that 0 FA rating(s) are green while.
- NUVL’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NUVL’s TA Score shows that 5 TA indicator(s) are bullish.
- NUVL’s TA Score: 5 bullish, 4 bearish.
Price Growth
NUVL (@Biotechnology) experienced а +5.02% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was +18.12%, and the average quarterly price growth was +72.90%.
Reported Earning Dates
NUVL is expected to report earnings on Nov 06, 2025.
Industries' Descriptions
@Biotechnology (+4.76% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| NUVL | XBI | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 82% | 4 days ago 90% |
| Stochastic ODDS (%) | 4 days ago 90% | 4 days ago 86% |
| Momentum ODDS (%) | 4 days ago 85% | N/A |
| MACD ODDS (%) | 4 days ago 76% | 4 days ago 86% |
| TrendWeek ODDS (%) | 4 days ago 83% | 4 days ago 88% |
| TrendMonth ODDS (%) | 4 days ago 81% | 4 days ago 88% |
| Advances ODDS (%) | 4 days ago 82% | 12 days ago 90% |
| Declines ODDS (%) | 14 days ago 78% | 4 days ago 90% |
| BollingerBands ODDS (%) | 4 days ago 85% | 4 days ago 88% |
| Aroon ODDS (%) | 4 days ago 79% | 4 days ago 87% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| ASVHX | 9.89 | 0.06 | +0.61% |
| American Century Small Cap Value G | |||
| LVAEX | 29.05 | 0.16 | +0.55% |
| LSV Value Equity Investor | |||
| MDDRX | 7.74 | 0.04 | +0.52% |
| MassMutual Diversified Value R4 | |||
| HEORX | 18.49 | -0.05 | -0.27% |
| Hartford Climate Opportunities R3 | |||
| VEMIX | 34.24 | -0.15 | -0.44% |
| Vanguard Emerging Mkts Stock Idx Instl | |||